Microbiological characteristics and clinical profile of Stenotrophomonas maltophilia infections in a teaching hospital in northeastern Brazil
DOI:
https://doi.org/10.30968/rbfhss.2024.153.1109Abstract
Objective: This study aimed to elucidate the microbiological and clinical characteristics of patients affected by infection caused by S.maltophilia in a tertiary hospital in the north-east of Brazil. Methodology: The study consisted of a retrospective analysis of microbiological samples from January 2022 to September 2023 from the microbiology department of the Walter Cantídio University Hospital, Fortaleza, Ceará. The prevalence of these infections was determined, along with the epidemiology and antimicrobial sensitivity profile to sulphamethoxazole/trimethoprim (SMX-TMP) and levofloxacin. Clinical characteristics of the affected patients were identified, such as the use of mechanical ventilation (MV), hemodialysis (HD), previous use of antimicrobials and the outcome of these patients. Results: The prevalence of S.maltophilia infections was 1.79% in the period (35 positive samples and 26 affected patients). Of the positive clinical isolates, there was a predominance from the respiratory tract, with 23 samples (61.43%) from tracheal aspirates and 5 samples from bronchoalveolar lavage (14.57%). The highest number of positive samples was identified in the clinical ICU (23 isolates). About SMX-TMP, 65.71% of the strains were sensitive to increased exposure, 5.71% were fully sensitive and 28.57% were resistant. A profile of strains predominantly sensitive to levofloxacin was observed (91.49%), with 5.71% of the isolates proving sensitive by increasing exposure and 2.85% proving resistant. Women were more affected (57.69%). The average age was 54.33 years. Patients undergoing HD during the infection accounted for 53.84% of the profile obtained, while the use of MV occurred in around 69.23% of those infected. All patients had previously used antimicrobials. 19 patients (69.23%) died and only 7 were discharged from hospital (30.76%). Conclusion: With the findings, it was possible to determine a predominant profile of critically ill patients, with greater involvement of the respiratory tract. We also identified considerable rates of resistance to SMX-TMP, as well as an association between S. maltophilia infection and death.
Downloads
References
Suetens C, Latour K, Kärki T, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two european point prevalence surveys, 2016 to 2017. Euro surveill, 2018; 23(46):1–18. DOI: 10.2807/1560-7917.ES.2018.23.46.1800516.
Allegranzi B, Bagheri NS, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet, 2011;377 (9761):228–241. DOI: 10.1016/S0140-6736(10)61458-4.
CDC. 2019. Antibiotic resistance threats in the United States, 2019. Disponível em: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Acessado em 11/02/2023.
Kingwell K. New antibiotic hits gram-negative bacteria. Nat. Rev. Drug Discov, 2018; 7(11): 2018. DOI:10.1038/nrd.2018.182.
Sader HS, Mendes RE, Streit JM, et al. Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020). Diagn Microbiol Infect Dis, 2022; 102: 115557. DOI: 10.1016/j.diagmicrobio.2021.115557.
Fruci M, Poole K. Aminoglycoside-inducible expression of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: involvement of the envelope stress-responsive AmgRS two-component system. PLoS One, 2018; 13(10):e0205036. DOI: 10.1371/journal.pone.0205036.
Aliskan AO, Alocilja EC. A Review of Carbapenem Resistance in Enterobacterales and Its Detection Techniques. Microorganisms, 2023; 3;11(6):1491. DOI: 10.3390/microorganisms11061491.
Brooke JS. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev, 2012; 25(1):2–41. DOI: 10.1128/CMR.00019-11.
Duan Z, Qin J, Liu Y, et al. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital. BMC Microbiol, 2020;20(1):1–9. DOI: 10.1186/s12866-020-01985-3.
Lira F, Berg G, Martínez JL. Double-face meets the bacterial world: The opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol, 2017;8(11): 1–15. DOI: 10.3389/ fmicb.2017.02190.
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infectious Diseases, 2022;74(12):2089–2114. DOI: 10.1093/cid/ciab1013.
Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infec Dis, 2009;9(5):312–323. DOI: 10.1016/S1473- 3099(09)70083-0.
Sánchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol, 2015;6(5):1–7. DOI: 10.3389/fmicb.2015.00658.
Tada T, Miyoshi T, Shimada K et al. Novel 6’-N-Aminoglycoside Acetyltransferase AAC(6’)-Iaj from a Clinical Isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2013; 57(1):96–100. DOI: 10.1128/AAC.01105-12.
Crossman LC, Gould VC, Dow JM. et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol, 2008;9(4):R74. DOI: 10.1186/gb-2008-9-4-r74.
Gibb J, Wong DW. Antimicrobial treatment strategies for Stenotrophomonas maltophilia: A focus on novel therapies. Antibiotics, 2021;10(10): 1226.
Rodrigues L, Gioia, T, Rossi, F. Stenotrophomonas maltophilia: resistência emergente ao SMX-TMP em isolados brasileiros. Uma realidade? J. Bras. Patol. Med. Lab., 2011; 47(5):511– 517. DOI:10.1590/S1676-24442011000500004.
Bueno JD, Lopes GU. Perfil de suscetibilidade aos antimicrobianos de isolados de Stenotrophomonas maltophilia em hospital pediátrico e comparação entre os métodos de disco-difusão e microdiluição em caldo, Repositório Universitário de Ânima, 2023.
Lemos MC, Paixão FC, Santos MA, et al. Isolados de Stenotrophomonas maltophilia em um hospital terciário no nordeste do Brasil. Braz. J. Health Rev, 2019;2(4): 3333–3367. DOI: https://doi.org/10.34119/bjhrv2n4-099.
BRCAST. Tabela de Pontos de Corte Clínicos do BrCAST - EUCAST. Brazilian Committee on Antimicrobial Susceptibility Testing, 2023.
CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Clinical and Laboratory Standards Institute, 2023. Disponível em: https://clsi.org/media/1632/m07a10_sample.pdf. Acesso em: 22 de novembro 2023.
Jia W, Wang J, Xu H, et al. Resistance of Stenotrophomonas maltophilia to fluoroquinolones: Prevalence in a university hospital and possible mechanisms. Int J Environ Res Public Health, 2015;12(5):5177-5195. DOI: 10.3390/ijerph120505177.
Dias VC, Bastos NA, Cotta RG, et al. Prevalência e resistência a antibióticos de Stenotrophomonas maltophilia em amostras clínicas: estudo epidemiológico de 10 anos. HU Rev, 2020;45(4): 402–407.
Vidigal PG, Dittmer S, Steinmann E, et al. Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol, 2014 Jul;304(5-6):613-619. DOI: 10.1016/j.ijmm.2014.04.002.
Çıkman A, Parlak M, Bayram Y, et al. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens. Afr Health Sci, 2016;16(1):149-52. DOI: 10.4314/ahs.v16i1.20.
Juhász E, Krizsán G, Lengyel G, et al. Infection and colonization by Stenotrophomonas maltophilia: Antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob, 2014;31:333. DOI: 10.1186/s12941-014-0058-9.
Rhoads DD. Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies. J Clin Microbiol, 2021;59(9):e0109421. DOI: 10.1128/JCM.01094-21.
Abusin S, Johnson S. Sulfamethoxazole/Trimethoprim induced liver failure: a case report. Cases J. 2008;1(1):44. DOI: 10.1186/1757-1626-1-44.
Kocak Z, Hatipoglu CA, Ertem G, et al. Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. J Infect. 2006;52(2):e49-52. DOI: 10.1016/j.jinf.2005.05.008.
Gordin F, Gibert C, Schmidt ME. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. Am J Med. 1994;96(1):94-5. DOI: 10.1016/0002-9343(94)90124-4.
Silva, CNGN. Infecção por Stenotrophomonas maltophilia em hospital terciário em Goiânia: características clínicas e microbiológicas e fatores de risco para letalidade. 2014. 103 f. Dissertação (Mestrado em Medicina Tropical e Saúde Publica) - Universidade Federal de Goiás, Goiânia, 2014.
Gracia-Paez JI, Ferraz JR, Silva IA, et al. Variantes de Smqnr de isolados clínicos de Stenotrophomonas maltophilia no Brasil. Rev Inst Med Trop Sao Paulo, 2013; 55(6):417-420. DOI: 10.1590/S0036-46652013000600008.
Travassos LH, Pinheiro MN, Coelho FS, et al. Phenotypic properties, drug susceptibility and genetic relatedness of Stenotrophomonas maltophilia clinical strains from seven hospitals in Rio de Janeiro, Brazil. J Appl Microbiol, 2004;96(5):1143-50, DOI:10.1111/j.1365-2672.2004.02248.x, 2004.
Braga FS. Stenotrophomonas maltophilia isoladas de pacientes com fibrose cística e sem fibrose cística: caracterização molecular da resistência a antimicrobianos. 2016. 88 f. Dissertação (Mestrado em Microbiologia Médica Humana) – Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2016.
Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis, 2022;9(2):ofab644. DOI: 10.1093/ofid/ofab644.
Chang YT, Lin CY, Lu PL, et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. J Microbiol Immunol Infect, 2014;47(1):28-35. DOI: 10.1016/j.jmii.2012.08.014.
Jeon YD, Jeong WY, Kim MH, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine, 2016;95(31):e4375. DOI: 10.1097/MD.0000000000004375.
Jian J, Xie Z, Chen L. Risk Factors for Mortality in Hospitalized Patients with Stenotrophomonas maltophilia Bacteremia. Infect Drug Resist, 2022; 1;15:3881-3886. DOI: 10.2147/IDR.S371129.
Lipuma JJ. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas , Delftia , and Acidovorax. In: Manual of Clinical Microbiology. Washington, DC, USA: ASM Press, 2015. p. 791–812.
Mutlu M, Yilmaz G, Aslan Y, et al. Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates. J Microbiol Immunol Infect, 2011; 44(6), 467–472, DOI:10.1016/j.jmii.2011.04.014.
Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: An Analysis of 45 Episodes. J Infect, 2002;45(1):47-53. DOI: 10.1053/jinf.2002.0978.
Nseir S, Di Pompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care. 2006;10(5):R143. DOI: 10.1186/cc5063.
Tseng CC, Fang W, Huang K, et al. Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia. Infect Control Hosp Epidemiol, 2009;30(12):1193-1202. DOI:10.1086/648455.
Hafiz TA, Aldawood E, Albloshi A, et al. Stenotrophomonas maltophilia Epidemiology, Resistance Characteristics, and Clinical Outcomes: Understanding of the Recent Three Years’ Trends. Microorganisms, 2022;10(12):2506. DOI: 10.3390/microorganisms10122506.
Kim EJ, Kim YC, Ahn JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis, 2019;19(1):754. DOI: 10.1186/s12879-019-4394-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
